Your browser is no longer supported. Please, upgrade your browser.
Settings
ADRO Aduro BioTech, Inc. daily Stock Chart
ADRO [NASD]
Aduro BioTech, Inc.
Index- P/E- EPS (ttm)-1.23 Insider Own0.90% Shs Outstand83.18M Perf Week3.80%
Market Cap158.87M Forward P/E- EPS next Y-0.88 Insider Trans-6.73% Shs Float46.12M Perf Month-41.05%
Income-97.30M PEG- EPS next Q-0.18 Inst Own48.00% Short Float4.13% Perf Quarter-51.15%
Sales12.40M P/S12.81 EPS this Y0.30% Inst Trans-4.18% Short Ratio4.55 Perf Half Y-27.38%
Book/sh1.45 P/B1.32 EPS next Y0.00% ROA-26.30% Target Price7.00 Perf Year-76.56%
Cash/sh3.21 P/C0.60 EPS next 5Y9.00% ROE-66.50% 52W Range1.70 - 8.40 Perf YTD-27.65%
Dividend- P/FCF- EPS past 5Y-36.20% ROI-74.30% 52W High-76.73% Beta1.72
Dividend %- Quick Ratio9.10 Sales past 5Y78.70% Gross Margin- 52W Low15.00% ATR0.22
Employees152 Current Ratio9.10 Sales Q/Q-40.90% Oper. Margin- RSI (14)36.24 Volatility6.91% 10.80%
OptionableYes Debt/Eq0.00 EPS Q/Q-6.60% Profit Margin- Rel Volume0.32 Prev Close1.91
ShortableYes LT Debt/Eq0.00 EarningsMay 08 Payout- Avg Volume418.89K Price1.96
Recom2.00 SMA20-16.31% SMA50-37.05% SMA200-49.83% Volume53,658 Change2.36%
Jun-03-19Downgrade Oppenheimer Outperform → Perform
Apr-15-19Initiated SVB Leerink Outperform $9
Feb-22-18Initiated Cantor Fitzgerald Overweight $15
Dec-13-17Reiterated H.C. Wainwright Buy $18 → $9.50
May-01-17Initiated Rodman & Renshaw Buy $18
May-17-16Reiterated FBR Capital Outperform $30 → $22
Mar-15-16Downgrade BofA/Merrill Buy → Underperform $32 → $14
Mar-02-16Initiated FBR Capital Outperform $30
Dec-01-15Downgrade Oppenheimer Outperform → Perform
Nov-24-15Reiterated ROTH Capital Buy $74 → $68
Oct-20-15Initiated Oppenheimer Outperform $30
May-11-15Initiated Leerink Partners Outperform $48
May-11-15Initiated Canaccord Genuity Buy $43
May-11-15Initiated BofA/Merrill Buy $40
Apr-20-15Initiated ROTH Capital Buy $74
Jun-04-19 10:32AM  Aduro Stock Crashes After ASCO Updates on Cancer Candidate Zacks
Jun-02-19 11:45AM  Aduro Biotech and Novartis Present Results from Ongoing Phase 1b Study of STING Agonist ADU-S100 (MIW815) in Combination with Anti-PD-1 Monoclonal Antibody Spartalizumab (PDR001) in Patients with Advanced Solid Tumors or Lymphomas GlobeNewswire
May-20-19 04:53PM  Health Care Digest: Cancer's show-and-tell meeting, a new biotech building rises and lupus patients' plea American City Business Journals
May-15-19 05:06PM  Aduro Biotech to Host Investor Event Featuring ADU-S100 (MIW815) Clinical Data Presented at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
05:05PM  Aduro Biotech Announces Clinical Program Update for Anti-APRIL Antibody BION-1301 GlobeNewswire
May-08-19 12:06PM  Aduro (ADRO) Q1 Earnings and Revenues Fall Shy of Estimates Zacks -21.09%
May-07-19 06:45PM  Aduro Biotech (ADRO) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:54PM  What's in Store for Axsome (AXSM) This Earnings Season? Zacks
04:05PM  Aduro Biotech Reports First Quarter 2019 Financial Results GlobeNewswire
10:53AM  Guardant Health (GH) to Report Q1 Earnings: What's in Store? Zacks
10:47AM  Proteostasis (PTI) to Post Q1 Earnings: What's in Store? Zacks
May-06-19 04:13PM  Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up? Zacks
03:06PM  What's in the Cards for Perrigo (PRGO) This Earnings Season? Zacks
11:54AM  Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up? Zacks
May-03-19 05:22PM  Mylan (MYL) to Report Q1 Earnings: What's in the Offing? Zacks
10:32AM  What's in Store for Sorrento (SRNE) This Earnings Season? Zacks
May-02-19 10:58AM  PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store? Zacks
May-01-19 06:07PM  Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings? Zacks
Apr-30-19 11:39AM  AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up? Zacks
09:15AM  Small Gains Still Bring New Highs Zacks
08:16AM  What's in the Cards for Bausch Health (BHC) Q1 Earnings? Zacks
Apr-29-19 06:14PM  Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings? Zacks
Apr-28-19 11:52PM  Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock? Zacks
10:47PM  Is a Beat in the Cards for Molina's (MOH) Earnings in Q1? Zacks
Apr-26-19 11:48AM  Universal Health (UHS) Q1 Earnings, Revenues Miss Estimates Zacks
11:42AM  What's in Store for HCA Healthcare's (HCA) Q1 Earnings? Zacks
11:38AM  Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings? Zacks
Apr-25-19 11:55AM  Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store? Zacks
11:15AM  Is a Beat in Store for Editas (EDIT) This Earnings Season? Zacks
09:27AM  The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences Zacks
Apr-24-19 04:32PM  What's in Store for Vertex (VRTX) This Earnings Season? Zacks
12:06PM  What's in the Cards for Amarin (AMRN) This Earnings Season? Zacks
11:43AM  Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock? Zacks
11:25AM  Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y Zacks
10:33AM  Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? Zacks
09:11AM  5 Biotech Stocks Defying the Medicare-for-All Scare Zacks
Apr-22-19 11:08AM  Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store? Zacks
10:33AM  Is a Beat in Store for AbbVie (ABBV) This Earnings Season? Zacks
08:15AM  Aduro Biotech Appoints Dimitry S.A. Nuyten, M.D., Ph.D. as Chief Medical Officer GlobeNewswire
Apr-18-19 04:05PM  Aduro Biotech Appoints Experienced Financial Executive, Frank Karbe, to its Board of Directors GlobeNewswire
Apr-17-19 04:05PM  Aduro Biotech Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire -7.59%
Apr-08-19 08:47AM  What Kind Of Shareholders Own Aduro BioTech, Inc. (NASDAQ:ADRO)? Simply Wall St.
Apr-01-19 08:00AM  Aduro Biotech to Present at the H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-27-19 10:48AM  Lilly (LLY) Signs New Immunology Deal With Private Biotech Zacks
Mar-07-19 08:00AM  Aduro Biotech to Present at Two Upcoming Investor Conferences in March GlobeNewswire
Mar-01-19 10:27AM  The Meet Group (MEET) to Report Q4 Earnings: What's in Store? Zacks
09:18AM  What Should We Expect From Aduro BioTech, Inc.s (NASDAQ:ADRO) Earnings In The Years Ahead? Simply Wall St.
Feb-28-19 04:13PM  Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates Zacks
09:07AM  Top Ranked Momentum Stocks to Buy for February 28th Zacks
08:00AM  Aduro Biotech Announces Upcoming Presentations at AACR Annual Meeting 2019 GlobeNewswire
Feb-27-19 04:05PM  Aduro Biotech Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
09:36AM  Top Ranked Momentum Stocks to Buy for February 27th Zacks
Feb-25-19 09:10AM  Will Aduro Biotech Continue to Surge Higher? Zacks
09:02AM  What's in Store for Universal Health (UHS) Q4 Earnings? Zacks
07:26AM  Top Ranked Momentum Stocks to Buy for February 25th Zacks
Feb-22-19 04:43PM  What's in Store for Vericel (VCEL) This Earnings Season? Zacks
Feb-21-19 08:55AM  Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings? Zacks +5.70%
08:15AM  Aduro Biotech to Present at the 8th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
08:00AM  Aduro Announces Changes to its Board of Directors GlobeNewswire
Feb-20-19 08:54AM  Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings? Zacks
07:35AM  What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings? Zacks
Feb-19-19 10:07AM  What's in Store for Sangamo (SGMO) This Earnings Season? Zacks
Feb-14-19 10:45AM  The Zacks Analyst Blog Highlights: BioDelivery, Cytokinetics, Celldex, Aduro and Aeterna Zacks
07:35AM  Consolidated Research: 2019 Summary Expectations for The Trade Desk, Aduro Biotech, Walker & Dunlop, California Resources, Century Casinos, and Arsanis Fundamental Analysis, Key Performance Indications GlobeNewswire
06:49AM  Will Aduro Biotech Continue to Surge Higher? Zacks
Feb-13-19 08:36AM  5 Tiny Biotech Stocks With Superb Growth Potential Zacks
Feb-12-19 06:29PM  Aduro Initiates Dosing in Phase I Melanoma Study on ADU-S100 Zacks
Feb-11-19 04:51PM  Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards? Zacks +5.37%
09:39AM  Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely? Zacks
08:00AM  Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma GlobeNewswire
Feb-08-19 10:00AM  AMAG Q4 Loss Narrower Than Expected, Revenues Lag Estimates Zacks
Feb-07-19 06:19AM  Will Aduro Biotech Continue to Surge Higher? Zacks
Feb-06-19 09:38AM  Top Ranked Momentum Stocks to Buy for February 6th Zacks
Jan-30-19 11:45PM  Why are deep-pocketed biotechs cutting hundreds of jobs? American City Business Journals +10.12%
08:00AM  Aduro Biotech Announces Strategic Reset GlobeNewswire
Jan-25-19 01:33PM  Is Aduro BioTech, Inc. (NASDAQ:ADRO) A Volatile Stock? Simply Wall St.
Jan-24-19 02:20PM  Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study Zacks
10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
10:08AM  Amicus (FOLD) Boasts Strong Pipeline Amid Stiff Competition Zacks
Jan-22-19 09:31AM  Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids Zacks
Jan-21-19 09:09AM  Aduro Biotech (ADRO) Upgraded to Strong Buy: What Does It Mean for the Stock? Zacks
Jan-03-19 08:00AM  Aduro Biotech to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.69%
Dec-24-18 09:53AM  Health Care Digest: 'Killing off' the JPM Week golden goose, a $75 million complement and more American City Business Journals
Dec-20-18 11:18AM  What You Must Know About Aduro BioTech, Inc.s (NASDAQ:ADRO) Financial Strength Simply Wall St.
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
06:50AM  Today's Research Reports on Trending Tickers: Aduro BioTech and Adial Pharmaceuticals ACCESSWIRE
Dec-19-18 12:30PM  These 4 Pharma Stocks Are Heating Up ACCESSWIRE +19.84%
10:23AM  Aduro Stock Surges on STING Activator Deal With Eli Lilly Zacks
09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
07:00AM  Today's Research Reports on Trending Tickers: Nektar Therapeutics and Aduro BioTech ACCESSWIRE
Dec-18-18 04:15PM  Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies PR Newswire -6.08%
Dec-12-18 08:00AM  Aduro Biotech Data Published in Cell Reports Highlights the Significant Role of the Magnitude of Intratumoral STING Activation by ADU-S100 in Anti-Tumor Immunity GlobeNewswire
Dec-05-18 06:08AM  Aduro Biotech Enters Oversold Territory Zacks
Dec-03-18 08:00AM  Aduro Biotech and Dana-Farber Cancer Institute Present Preclinical Data Supporting Anti-APRIL Antibody BION-1301 for the Treatment of Multiple Myeloma at the 60th American Society of Hematology Annual Meeting and Exposition GlobeNewswire
Nov-09-18 07:30AM  Aduro Biotech Presents Preliminary Results from Ongoing Phase 1 Trials of STING agonist ADU-S100 (MIW815) in Patients with Advanced Solid Tumors or Lymphomas GlobeNewswire -13.78%
Nov-06-18 04:16PM  Aduro to Host and Webcast an Investor Event to Review Data Presented at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire -6.47%
Nov-02-18 07:45AM  New Research: Key Drivers of Growth for Shutterfly, Aegion, Columbia Property Trust, Aduro Biotech, IQVIA, and Intelsat S.A Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-31-18 11:17AM  Aduro (ADRO) Q3 Loss Narrower Than Expected, Revenues Lag Zacks
Oct-30-18 07:00PM  Aduro Biotech (ADRO) Reports Q3 Loss, Misses Revenue Estimates Zacks
04:01PM  Aduro Biotech Reports Third Quarter 2018 Financial Results GlobeNewswire
Aduro BioTech, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck. It is also developing product candidates to prevent or control immune responses through the stimulator of interferon genes pathway. In addition, the company is developing BION-1301, a fully blocking humanized monoclonal anti-APRIL antibody that is in Phase I clinical trial for IgA nephropathy and multiple myeloma; and CD27, a co-stimulatory receptor, which is in preclinical studies expressed on different immune cells, such as T-lymphocytes and NK cells. It has collaboration agreements with Novartis Pharmaceuticals Corporation, Eli Lilly and Company, and Merck Sharp and Dohme B.V.; license agreements with Karagen Pharmaceuticals, Inc., UC Berkeley, and Memorial Sloan Kettering Cancer Center. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferber CelesteSVP, GC and SecretaryMay 20Sale3.212,0006,41329,436May 22 07:04 PM
Lew JenniferChief Financial OfficerMay 01Option Exercise1.2518,60223,306147,299May 03 07:17 PM
Lew JenniferChief Financial OfficerMay 01Sale4.2018,60278,136135,155May 03 07:17 PM
Lew JenniferChief Financial OfficerApr 08Option Exercise1.2518,60123,305147,299Apr 10 07:09 PM
Lew JenniferChief Financial OfficerApr 08Sale4.0718,60175,775135,155Apr 10 07:09 PM
van Elsas AndreaChief Scientific OfficerMar 19Sale3.966,08124,107239,557Mar 21 05:35 PM
van Elsas AndreaChief Scientific OfficerFeb 26Sale4.256,84429,120245,638Feb 27 07:07 PM
van Elsas AndreaChief Scientific OfficerDec 28Sale2.571,9074,901252,482Dec 31 04:02 PM
Lew JenniferChief Financial OfficerDec 12Sale2.931,0353,035135,155Dec 14 04:19 PM
Templeman BlaineChief Legal OfficerDec 12Sale2.931,2413,639129,878Dec 14 04:18 PM
ISAACS STEPHEN TPresident and CEODec 12Sale2.935,82917,091327,024Dec 14 04:17 PM
van Elsas AndreaChief Scientific OfficerDec 12Sale2.932,1716,365254,389Dec 14 04:15 PM
Templeman BlaineChief Legal OfficerNov 20Sale2.918432,453131,119Nov 20 07:58 PM
van Elsas AndreaChief Scientific OfficerSep 24Sale5.837,72645,022256,560Sep 25 08:11 PM
Templeman BlaineChief Legal OfficerSep 24Sale5.8110,26259,613131,119Sep 25 08:10 PM
Templeman BlaineExecutive VP, General CounselSep 13Sale6.506,05639,360141,381Sep 14 07:29 PM
van Elsas AndreaChief Scientific OfficerSep 13Sale6.509,75463,394264,286Sep 14 07:28 PM
Lew JenniferChief Financial OfficerSep 13Sale6.505,62336,546136,190Sep 14 07:27 PM
Sacks NatalieChief Medical OfficerSep 13Sale6.503,02819,680173,720Sep 14 07:25 PM
ISAACS STEPHEN TPresident and CEOSep 13Sale6.5024,143156,913332,853Sep 14 07:24 PM
ISAACS STEPHEN TPresident and CEOSep 06Option Exercise1.0046,98746,987252,733Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 06Sale7.9246,987372,024205,746Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 05Option Exercise1.0015,58515,585221,331Sep 06 07:42 PM
ISAACS STEPHEN TPresident and CEOSep 05Sale7.9015,585123,134205,746Sep 06 07:42 PM
Sacks NatalieChief Medical OfficerSep 04Sale7.134,50432,09989,548Sep 06 07:40 PM
van Elsas AndreaChief Scientific OfficerJul 17Sale6.9610,45472,803206,215Jul 19 07:39 PM